Effects of ODM-109 on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis

PHASE2CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

May 31, 2017

Study Completion Date

June 30, 2017

Conditions
Amyotrophic Lateral Sclerosis
Interventions
DRUG

ODM-109

ODM-109 1 mg capsule for oral administration.

DRUG

Placebo for ODM-109

Placebo capsule for oral administration.

Trial Locations (11)

Unknown

Charite Universitatsmedizin Berlin, Berlin

Medical School Hannover, Hanover

University Clinical Jena, Jena

University Hospital of Ulm, Ulm

Beaumont Hospital, Dublin

University Medical Centre Utrecht, Utrecht

Royal Sussex County Hospital, Brighton

The Walton Centre, Liverpool

London Kings College Hospital, London

Royal London Hospital, London

University of Sheffield, Sheffield

All Listed Sponsors
lead

Orion Corporation, Orion Pharma

INDUSTRY

NCT02487407 - Effects of ODM-109 on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis | Biotech Hunter | Biotech Hunter